We have filed a broad portfolio of new patent applications to protect our intellectual property.
In addition, VAL-083 has been granted Orphan Drug protection by the United States Food and Drug Administration (FDA) and the European Medicines Association (EMA). In addition to patents we may receive, Orphan Drug Protection permits us to sell VAL-083 as a treatment for glioma without competition for seven years in the United States and for ten years in the European Union following market approval, in respect of a medicinal product containing a similar active substance for the same indication.
We believe that our portfolio of Intellectual Property Rights provides a strong and defensible market position for the commercialization of VAL-083 and other anti-cancer products. DelMar will provide an opportunity to review our patent applications to investors who request such an opportunity and enter into a nondisclosure agreement with DelMar.